市場調査レポート

商品コード

1630635

膵臓がん治療市場規模、シェア、成長分析、治療タイプ別、診断別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025-2032年

Pancreatic Cancer Treatment Market Size, Share, Growth Analysis, By Treatment Type, By Diagnosis, By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年01月07日
発行: SkyQuest
ページ情報: 英文 165 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

膵臓がん治療の世界市場規模は2023年に28億米ドルと評価され、2024年の32億米ドルから2032年には92億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは14.2％で成長する見通しです。

膵臓がん治療市場は、米国がん協会によると、米国における全がん患者の約3％を占めるこの課題疾患の罹患率の上昇に牽引され、今後数年間で大きく成長する見通しです。膵臓がんは進行した段階で発見されることが多く、効果的な治療オプションに対する需要が高まっています。主な症状には黄疸や体重減少があり、危険因子は糖尿病から特定の化学物質への曝露まで多岐にわたります。企業が新型コロナウイルス感染症拡大後に事業を再構築し、社会的孤立やリモートワークによる初期の混乱を克服したことで、市場の拡大はさらに加速しています。腫瘍の特徴の理解が深まるにつれ、個別化された治療アプローチはこの攻撃的ながんを管理する上でますます重要になると思われます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Pfizer Inc.（USA）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Sanofi S.A.（France）
AstraZeneca PLC（UK）
GlaxoSmithKline plc（UK）
Johnson & Johnson（USA）
Abbott Laboratories（USA）
Sun Pharmaceutical Industries Ltd.（India）
Cipla Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Lupin Ltd.（India）
Teva Pharmaceutical Industries Ltd.（Israel）
Valeant Pharmaceuticals International（Canada）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
Takeda Pharmaceutical Company Limited（Japan）
Sinopharm（China）
Shanghai Fosun Pharmaceutical（Group）Co., Ltd（China）
EMS S.A.（Brazil）

結論と推奨事項

Product Code: SQMIG35I2262

Global Pancreatic Cancer Treatment Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.2 billion in 2024 to USD 9.25 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2025-2032).

The pancreatic cancer treatment market is poised for significant growth in the coming years, driven by the rising incidence of this challenging disease, which accounts for approximately 3% of all cancer cases in the U.S., according to the American Cancer Society. With pancreatic cancer often detected at advanced stages, the demand for effective treatment options is on the rise. Key symptoms include jaundice and weight loss, and risk factors range from diabetes to exposure to certain chemicals. The market's expansion is further bolstered by companies restructuring operations post-COVID-19, overcoming earlier disruptions from social isolation and remote work. As understanding of tumor characteristics deepens, personalized treatment approaches will become increasingly critical in managing this aggressive form of cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pancreatic Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pancreatic Cancer Treatment Market Segmental Analysis

Global Pancreatic Cancer Treatment Market is segmented by Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy and Others. Based on Diagnosis, the market is segmented into Blood Test, Biopsy, Imaging Tests and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.Based on diagnosis, the market is segmented into blood test, biopsy, imaging tests, others. By route of administration, the market is segmented into oral, parenteral, and others. By end-user, the market is segmented into hospitals, specialty clinics, homecare, and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on region, the pancreatic cancer treatment market segmentation spans North America, Europe, Asia-Pacific, South America, and MEA.

Driver of the Global Pancreatic Cancer Treatment Market

The global market for pancreatic cancer treatment is poised for significant growth primarily due to the rising prevalence of cancer and the corresponding demand for specialized care. With an increasing number of diagnoses linked to genetic factors such as BRCA2 gene mutations, Lynch syndrome, and familial atypical mole-malignant melanoma (FAMMM) syndrome, there is a heightened familial risk for cancer. Additionally, the growing rates of diabetes and obesity contribute to the escalating incidence of pancreatic cancer. Enhanced healthcare spending is also a vital driver, as it improves the existing infrastructure and promotes the development of treatment options. Government initiatives aimed at bolstering healthcare funding further influence market dynamics, paving the way for advancements in pancreatic cancer treatment solutions.

Restraints in the Global Pancreatic Cancer Treatment Market

The global pancreatic cancer treatment market is expected to encounter several restraints that could hinder its growth trajectory. Chief among these is the high cost of treatment, which poses a significant barrier for patients seeking care. Additionally, in many emerging regions, inadequate healthcare infrastructure and a scarcity of skilled medical professionals will further complicate access to effective treatment options. Between 2023 and 2030, stringent regulatory requirements coupled with insufficient public awareness about pancreatic cancer and available therapies are likely to further restrict market expansion, thereby creating challenges for stakeholders aiming to improve patient outcomes in this critical area.

Market Trends of the Global Pancreatic Cancer Treatment Market

The Global Pancreatic Cancer Treatment market is witnessing a significant surge driven by intensifying research and development (R&D) initiatives aimed at innovative therapeutic solutions. With a notable rise in drug discoveries and regulatory approvals, the landscape is becoming increasingly favorable for the introduction of novel treatments. These advancements not only enhance treatment efficacy but also broaden the range of options available to healthcare providers and patients. Furthermore, ongoing collaborations between pharmaceutical companies and research institutions are expected to facilitate the rapid development of targeted therapies, thereby propelling the market's growth trajectory and addressing the critical unmet needs in pancreatic cancer care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Pancreatic Cancer Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Others

Global Pancreatic Cancer Treatment Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
Blood Test
Biopsy
Imaging Tests
Others

Global Pancreatic Cancer Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Parenteral
Others

Global Pancreatic Cancer Treatment Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Pancreatic Cancer Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Pancreatic Cancer Treatment Market Size & CAGR (2025-2032)

North America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
- US
- Canada
Europe (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valeant Pharmaceuticals International (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinopharm (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EMS S.A. (Brazil)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

膵臓がん治療市場規模、シェア、成長分析、治療タイプ別、診断別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025-2032年

Pancreatic Cancer Treatment Market Size, Share, Growth Analysis, By Treatment Type, By Diagnosis, By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

膵臓がん治療市場規模：治療のタイプ別

膵臓がん治療市場規模：診断別

膵臓がん治療市場規模：投与経路別

膵臓がん治療市場規模：エンドユーザー別

膵臓がん治療市場規模：流通チャネル別

膵臓がん治療市場規模